Although not employed currently as a routine clinical screening method for HLRCC, we acquired an antibody directed against FH (J-13 fumarate hydratase, Santa Cruz Biotechnology, Santa Cruz, CA) and performed staining on the lesion using two benign uterine leiomyomas as positive controls. Here, FH is linked to hereditary leiomyomatosis and renal cell cancer.